Latest news for SanBio (OTC:SNBIF) Stock

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co Ltd

Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –
– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –
– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –
– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –

News

Reported Earlier, Vir Biotechnology Announces Phase 2 Data And Phase 3 Launch For Chronic Hepatitis Delta Treatment

SYRE

Reported Earlier, Spyre Therapeutics Prices $200M Public Offering Of 7.275M Common Shares At $27.50/Share

The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $6.9 million before deducting the placement agent's fees and other offering expenses payable by the Company. The offering is expected to close on or about November 20, 2024, subject to the satisfaction of customary closing conditions.

HCWB

Reported Earlier, HCW Biologics Announces $6.9M Direct Offering And Private Placement Priced Above Market

Select intends to use the net proceeds of the Offering, together with the proceeds from the proposed new incremental term loan and cash on hand, to repay in full the term loans currently outstanding under Select's existing senior secured credit agreement, to redeem all of Select's outstanding 6.250% senior notes due 2026 and to pay fees and expenses related to the foregoing.&nbsp;

Reported Earlier, Select Medical Announces Pricing of $550M 6.250% Senior Notes Due 2032

The fundamentals of our business are strong. Our AirSCWO technology is performing well across biosolid/sludge and liquid waste streams. Our DaaS business is taking shape representing near-term recurring revenue, with our first operating site being actively negotiated to destroy non-hazardous waste, and our conversations are advancing with TSDF operators for onsite non-hazardous and hazardous waste destruction. Our approach to opening markets is bearing fruit with opportunities across AFFF, GAC, IX, and other organic waste streams. Our current backlog/pipeline exceeds $1.8B and we believe this will grow further.

SCWO

Reported Earlier, 374Water Highlights Commercial Milestones, $1.8B Pipeline, And Growing Opportunities In Waste Management

Telix's development program will initially focus on the treatment of bladder cancer, rounding out its urology franchise, which includes late-stage therapeutic programs for kidney and prostate cancers.
FAP is a pan-cancer marker expressed in the tumor microenvironment of epithelial cancers and on the surface of some specific cancer types, including sarcomas and mesotheliomas.

Reported Earlier, Telix Expands Theranostic Pipeline With FAP-Targeting Radiopharmaceuticals For Pan-Cancer Treatment

The Company stated that while its financial position remains sound, the Board of Directors determined that the reduction in the dividend was prudent given the Company's recent operating performance. As previously disclosed, the Company has been implementing multiple initiatives to improve performance that have led to year-over-year performance improvement. These include price adjustments with our customers and cost reduction projects, including the previously disclosed consolidation of the&nbsp;Albia, Iowa operation into the Tyrone, Pennsylvania operation.

Reported Earlier, Chicago Rivet & Machine Reduces Quarterly Dividend To $0.03 Per Share From $0.10 Per Share, Payable December 20, 2024

Earnings

ZENV

Reported Earlier, Zenvia Q3 Sales R$284.400M Beat R$249.810M Estimate; Net Income R$52.62M Up From Net loss R$11.94M

ZEPP

Reported Earlier, Zepp Health Q3 EPS $(0.78) Down From $0.12 YoY, Sales $42.50M Down From $82.53M YoY

<ul>
<li>IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL</li>
<li>IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a range of B-NHL cell lines, in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patients</li>
<li>In vivo studies further validated that IPH6501 augments the ability of peripheral NK cells to migrate and infiltrate tumors</li>
<li>Results support clinical development of IPH6501 in R/R B-NHL</li>
</ul>

IPHA

Innate Pharma Publishes Preclinical Data Demonstrating The Potential Of IPH6501 In Science Immunology

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) to report quarterly earnings at 53 cents per share on revenue of $167.72 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Walmart shares rose 1.6% to $85.44 in after-hours trading.</li>
<li>AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) reported better-than-expected earnings for its fourth quarter. The company's quarterly earnings came in at $1.27 per share which beat the analyst consensus estimate of $1.24 per share. The company reported quarterly sales of $4.11 billion versus the analyst consensus estimate of $4.14 billion. Aecom shares fell 1.2% to $107.80 in the after-hours trading session.</li>
<li>Analysts expect Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) to post quarterly earnings at $2.82 per share on revenue of $19.94 billion. The company will release earnings before the markets open. Lowe&#8217;s shares gained 0.1% to $272.10 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) reported better-than-expected results for its fourth quarter on Monday. For the first quarter of fiscal 2025, Symbotic expects revenue of $495 million to $515 million, versus the $495.73 million estimate, and adjusted EBITDA of $27 million to $31 million. Symbotic shares jumped 26.3% to $38.60 in the after-hours trading session.</li>
<li>Analysts expect Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) to report quarterly earnings at $1.25 per share on revenue of $8.27 billion before the opening bell. Medtronic shares gained 0.2% to $87.74 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>
Image via Wikimedia Commons

Pre-Market Outlook

Markets

Trading Ideas

Walmart, Lowe's And 3 Stocks To Watch Heading Into Tuesday

<ul>
<li>Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activity</li>
<li>A greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care alone</li>
<li>Systemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ systems, primarily in women, for whom there is a significant need for additional treatment options</li>
</ul>

BIIB

UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction

The Airline Offers New Low-Cost Travel Options to Popular Destinations in 51 Cities

ALGT

Reported Earlier, Allegiant Expands Nationwide With 44 Routes And $39 Fares, Adding Gulf Shores, Columbia, And Colorado Springs

Creates a leading North American lithium producer and developer
<ul>
<li>Piedmont and Sayona to combine in all-stock merger with ownership split of approximately 50% / 50% on a fully diluted basis immediately post-merger and prior to the conditional equity raising</li>
<li>Creating a leading North American hard rock lithium producer with geographically advantaged spodumene resources of global scale</li>
<li>Simplified corporate structure aligns North American Lithium ("NAL") offtake economics, and removes contractual complexities</li>
<li>Unified ownership of NAL unlocks the potential for a significant brownfield expansion</li>
<li>Combined scale provides strategic flexibility to combine and optimize downstream strategies</li>
<li>Material corporate, logistics, marketing, and procurement synergies</li>
<li>Significantly strengthened balance sheet with two stage equity financing, with post-merger raise led by cornerstone subscription from Resource Capital Fund VIII L.P. ("RCF VIII"), associated with Resource Capital Funds ("RCF"), a critical minerals and mining-focused global investment firm</li>
<li>MergeCo will endeavor to complete an additional equity raise for eligible retail shareholders post-closing</li>
</ul>

Reported Earlier, Piedmont And Sayona Merge To Form North America's Largest Hard Rock Lithium Producer

2025 Outlook
The Company's practice is to provide annual guidance, excluding the impact of future acquisitions, dispositions and transaction-related costs.
The Company is providing the following outlook for the fiscal year ending September 30, 2025, which remains unchanged from the previous guidance included in the Company's earnings release issued on August 8, 2024:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(in thousands, except share and per share amounts)</td>
<td colspan="5" rowspan="1">Outlook Range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="5" rowspan="1">Fiscal year ending September 30, 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">243,000</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">263,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (non-GAAP)</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">63,000</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">71,500</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and internally developed software amortization</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">12,000</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">14,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash interest expense</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1,000</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pro forma adjusted diluted earnings per share(1)(non-GAAP)</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1.05</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1.25</td>
</tr>
</tbody>
</table>
</figure>

Guidance

IIIV

i3 Verticals Reaffirms FY25 Guidance: Sees Pro Forma EPS From Continuing Operations Of $1.05-$1.25, Revenue From Continuing Operations Of $243M-$263M

Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and&nbsp;Elon Musk&#8217;s SpaceX&nbsp;may encounter obstacles in their attempts&nbsp;to block the National Labor Relations&nbsp;Board or NLRB cases.
What Happened: On Monday, a panel of U.S. judges suggested that both companies might have prematurely brought their challenges to the NLRB&#8217;s structure to&nbsp;the 5th U.S. Circuit Court&nbsp;of Appeals, reported Reuters.
The panel&nbsp;questioned whether Amazon and SpaceX&nbsp;should have allowed more time for Texas judges&nbsp;to rule before filing appeals.
The legal challenges, if successful, could potentially weaken the NLRB&#8217;s powers. Even if they fail, some have already managed to indefinitely delay NLRB cases.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42026410/nvidia-apple-suppliers-prepare-for-policy-shifts-japans-ai-leap-and-amds-workforce-cut-this-week-in-ai?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nvidia, Apple Suppliers Prepare For Policy Shifts, Japan&#8217;s AI Leap, And AMD&#8217;s Workforce Cut: This Week In AI</a>
Amazon and SpaceX are separately trying to block NLRB&nbsp;cases accusing them of illegal&nbsp;labor practices.
Amazon is fighting a case related to its first-ever union at a warehouse in New York City. SpaceX is facing accusations of firing engineers who criticized Musk — a claim the company denies.
Amazon and SpaceX argue that&nbsp;federal judges in Texas &#8220;effectively&nbsp;denied&#8221; their petitions to block&nbsp;NLRB cases&nbsp;by not ruling on them&nbsp;promptly. However, the judges in both cases&nbsp;ruled that the lawsuits did&nbsp;not belong in Texas.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: This development follows a series of legal disputes involving the NLRB and major corporations.
Other companies, <a href="https://www.benzinga.com/markets/equities/24/08/40570061/chipotle-accused-by-labor-watchdog-of-unlawfully-withholding-pay-raises-from-unionized-workers">including</a>&nbsp;Chipotle Mexican Grill&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>),&nbsp;Stellantis&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>), and&nbsp;Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), have <a href="https://www.benzinga.com/markets/equities/24/10/41136199/apple-accused-of-violating-federal-law-over-alleged-illegal-employee-agreements-nlrb-hearing-set">also faced NLRB</a> complaints for <a href="https://www.benzinga.com/news/24/09/40894503/uaw-files-nlrb-complaint-against-stellantis-over-alleged-contract-violations-says-it-intends-to-make">alleged labor violations</a>.
Earlier this year,&nbsp;Amazon argued that the <a href="https://www.benzinga.com/news/24/02/37191759/jeff-bezos-amazon-joins-spacex-and-trader-joes-in-slamming-nlrb-amid-labor-union-dispute">NLRB was unconstitutional</a>&nbsp;in response to a case accusing the company of unlawfully retaliating against workers who voted to unionize.
In October, the&nbsp;<a href="https://www.benzinga.com/government/24/10/41171072/amazon-accused-of-union-busting-after-drivers-unionize-nlrb-files-complaint">NLRB charged Amazon</a>&nbsp;for failing to acknowledge and bargain with the Teamsters Union.
In SpaceX&#8217;s case, NLRB alleged that the company violated federal labor laws by firing employees who, in June 2022, circulated a letter criticizing Musk's controversial tweets and calling him a &#8220;<a href="https://www.benzinga.com/news/24/01/36484393/spacex-wrongfully-fired-employees-who-called-elon-musk-distraction-and-embarrassment-us-labor-agency">distraction and embarrassment</a>.&#8221;
Price Action: Amazon shares closed Monday's session down 0.45% at $201.70. In after-hours trading, the stock gained slightly, reaching $201.89 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo Courtesy: T. Schneider On Shutterstock.com
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41872302/taylor-swift-fans-abandon-elon-musks-x-for-bluesky-how-trumps-election-victory-triggered-swifties-uprising?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Taylor Swift Fans Abandon Elon Musk&#8217;s X For Bluesky, Says Report: How Trump&#8217;s Election Victory Triggered Swifties Uprising</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Politics

Tech

Media

AAPL

AMZN

STLA

Amazon And SpaceX's Efforts To Block NLRB Cases In Jeopardy As Appeals Court Raises Key Legal Concerns

i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $0.17 by 11.76 percent. This is a 6.25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $60.864 million which missed the analyst consensus estimate of $61.250 million by 0.63 percent. This is a 36.87 percent decrease over sales of $96.407 million the same period last year.

Earnings Misses

i3 Verticals Q4 2024 Adj. EPS $0.15 Misses $0.17 Estimate, Sales $60.864M Miss $61.250M Estimate

Asset management firm&nbsp;Ark Invest recently expressed a bullish view on the future of real-world asset (RWA) tokenization and its potential impact on the broader digital assets industry.
What Happened: In the weekly newsletter shared Monday, the Cathie Wood-led firm Ark Invest spoke about Tether&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) latest move into the RWA tokenization space. 
Tether, the largest stablecoin issuer, launched Hadron, a platform that enables users to tokenize virtually anything, from commodities and corporate equity to government debt and corporate bonds.
Ark Invest believed that the launch of Hadron signaled a growing appetite for tokenization, which was still a very nascent industry. The total value of tokenized RWAs was only $11 billion, a minuscule percentage of the ~$500 trillion total addressable market.
&#8220;In our view, Tether is extremely well positioned to be a leader in this space, as RWAs represent a natural extension of its core business—tying digital assets to fiat currencies,&#8221; the firm noted.
See Also: <a href="https://www.benzinga.com/general/social-media/24/11/42048594/trump-digs-deeper-into-cryptocurrency-bakkt-shares-soar-on-reported-interest-from-president-elects-media-company">Trump Digs Deeper Into Cryptocurrency? Bakkt Shares Soar On Reported Interest From President-Elect&#8217;s Media Company</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://t.co/ZZKfY4RPMk">https://t.co/ZZKfY4RPMk</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1858571067066925241?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
RWAs are physical or off-chain assets, such as real estate, commodities, art, and financial instruments like bonds or equities, that can be represented digitally, or tokenized, on public blockchains.
Tokenization allows users to trade digital representations of assets, making them more liquid and, because of blockchain technology, more transparent.
Why It Matters: For the curious, RWAs are physical or off-chain assets, such as real estate, commodities, art, and financial instruments like bonds or equities, that can be represented digitally, or tokenized, on public blockchains.
Tokenization allows users to trade digital representations of assets, making them more liquid and, because of the immutable-nature of blockchain technology, more transparent.
The world's largest asset manager, BlackRock entered the sector with the introduction of its tokenized U.S. Treasury product, BUIDL, built atop Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), earlier this year. As of this writing, it boasted of a market capitalization of $541.79 million, <a href="https://app.rwa.xyz/assets/BUIDL">according </a>to RWA market tracker Rwa.xyz.
According to Prophecy Market Insights, the real estate tokenization market was valued at&nbsp;$3.8 billion&nbsp;in 2024 and is&nbsp;<a href="https://www.prophecymarketinsights.com/market_insight/Global-Real-Estate-Tokenization-Market-4857" target="_blank" rel="noreferrer noopener">expected&nbsp;</a>to reach $26 billion by 2034 with a compound annual growth rate (CAGR) of 2.90%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42049664/paul-tudor-jones-boosts-bitcoin-holdings-potentially-making-btc-his-largest-non-options-investment">Paul Tudor Jones Boosts Bitcoin Holdings, Potentially Making BTC His Largest Non-Options Investment</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$USDT

Cathie Wood's Ark Bullish On $500T Tokenization Market As Tether Enters Race

In a recent episode of the &#8220;All-In Podcast,&#8221; <a href="https://www.benzinga.com/24/11/42025179/chamath-palihapitiya-regrets-this-3-or-4-billion-crypto-mistake-as-bitcoin-rises-above-90000-would-have-made-a-lot-more-money">Chamath Palihapitiya expressed </a>skepticism about a potential boom in mergers and acquisitions (M&amp;A) for the year 2025. He suggests that the market will remain restrained, contrary to popular expectations.
What Happened: During the discussion, Palihapitiya highlighted, &#8220;I think it&#8217;s going to still be pretty subdued,&#8221; he said. &#8220;I don&#8217;t think that you&#8217;re going to see these crazy M&amp;A deals that I think everybody is expecting. I also don&#8217;t anticipate a lot of these big companies going public, at least in the first half of the year.&#8221;
He attributes this to the prevailing interest rates, which he argues are not conducive for companies that missed the opportunity to go public when rates were more favorable.
Palihapitiya further elaborated on the current economic conditions, noting that high interest rates make it challenging to execute substantial M&amp;A deals or IPOs. He emphasized that successful M&amp;A should be driven by industrial logic rather than regulatory uncertainties.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">saturday special&#8230; besties are back! (0:00) bestie intros! (7:57) election impact on <a href="https://twitter.com/hashtag/bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#bitcoin</a>, crypto, and fintech stocks (21:56) m&amp;a and ipos: what to expect in 2025 (39:52) pharma ads on cable tv: should it be allowed? is big pharma buying influence? (58:17) fbi raids… <a href="https://t.co/HBDXSVo7LD">pic.twitter.com/HBDXSVo7LD</a>
&mdash; The All-In Podcast (@theallinpod) <a href="https://twitter.com/theallinpod/status/1857835928343195777?ref_src=twsrc%5Etfw">November 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42014985/matt-gaetz-to-be-confirmed-as-attorney-general-in-a-trump-administration-not-so-fast-polymarket-traders-say?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Matt Gaetz To Be Confirmed As Attorney General In A Trump Administration? Not So Fast, Polymarket Traders&nbsp;Say</a>
Additionally, Palihapitiya pointed out the appeal of risk-free returns, with figures like Warren Buffett investing heavily in T-bills, making large IPOs less attractive compared to the uncertain stock market.
Why It Matters: The anticipation of a surge in M&amp;A activity has been a topic of discussion, especially with the potential policy shifts under the upcoming Trump administration. According to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">analysts</a>, the Republican control of Congress could lead to a more favorable environment for deal-making. This includes the possibility of removing Federal Trade Commission Chair Lina Khan, known for her aggressive antitrust stance, which has been a significant barrier to M&amp;A activity.
Furthermore, Jim Cramer expressed optimism <a href="https://www.benzinga.com/m-a/24/11/41805370/jim-cramer-hopes-m-a-to-come-back-bigly-under-trump-administration">about a resurgence in M&amp;A</a> under the Trump administration, predicting a more lenient approach to M&amp;A approvals. He highlighted the potential benefits for the regional banking sector, which could see growth through acquisitions or mergers to form larger entities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42022585/michael-van-de-poppe-says-bitcoin-ethereum-and-altcoins-close-to-the-point-where-investors-can-buy-the-dip?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Michael Van De Poppe Says Bitcoin, Ethereum And Altcoins Close To The Point Where Investors Can &#8216;Buy The&nbsp;Dip&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

General

Chamath Palihapitiya Says Don't Expect 'Crazy M&A Deals' In 2025

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) will release earnings results for its fourth quarter, after the <a href="https://www.benzinga.com/quote/ACM/earnings">closing bell on Monday, Nov. 18</a>.
Analysts expect the Dallas, Texas-based company to report quarterly earnings at $1.25 per share, up from $1.01 per share in the year-ago period. The company projects to report quarterly revenue of $4.12 billion, compared to $3.84 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Oct, 31, Aecom was selected for a $90 million single-award task order for the G7 Partnership for Global Infrastructure and Investment.
Aecom shares fell 0.3% to close at $106.93 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/ACM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/643e5abb9eebb2000134dbb9/sangita-jain">Keybanc analyst Sangita Jain</a> maintained an Overweight rating and raised the price target from $115 to $122 on Nov. 7. This analyst has an accuracy rate of 81%.</li>
<li>Citigroup analyst Andrew Kaplowitz maintained a Buy rating and increased the price target from $110 to $128 on Oct. 22. This analyst has an accuracy rate of 87%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac4af1b85e930001e6383a/jamie-cook">Truist Securities analyst Jamie Cook </a>maintained a Buy rating and raised the price target from $108 to $119 on Oct. 4. This analyst has an accuracy rate of 68%.</li>
<li>Baird analyst Andrew Wittmann maintained an Outperform rating and boosted the price target from $96 to $100 on Aug. 7. This analyst has an accuracy rate of 78%.</li>
<li>RBC Capital analyst Arthur Nagorny maintained an Outperform rating and increased the price target from $112 to $113 on Aug. 7. This analyst has an accuracy rate of 67%.</li>
</ul>
Considering buying ACM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="445" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18023108/image-174-1024x445.png" alt="" class="wp-image-652292" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18023108/image-174-1024x445.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18023108/image-174-300x130.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18023108/image-174-768x333.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18023108/image-174-1536x667.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18023108/image-174.png 1617w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Price Target

Analyst Ratings

Aecom Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. announces conditional and time-limited approval for its ‘AKUUGO Suspension for Intracr...

SanBio's AKUUGO Suspension Nears Market Launch

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has updated stakeholders on the approval process of their AKUUGO suspension for intrac...

SanBio Co. Clarifies AKUUGO Suspension Approval

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has announced new research findings that detail the mechanisms of action for its key p...

SanBio Reveals Breakthrough in Brain Regeneration Research

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has announced that the US Patent and Trademark Office has granted a Notice of Allowanc...

SanBio Co. Granted US Patent for Stroke Cell Therapy

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has announced the conditional and time-limited marketing approval in Japan for ‘AKUUGO...

SanBio's Revolutionary TBI Treatment Approved

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. announced that its development product SB623, aimed at treating chronic motor paralysi...

SanBio's SB623 Shows Long-Term Motor Function Improvements

SanBio Co (JP:4592) has released an update. SanBio Co., a company listed on the TSE Growth market, has released its financial results for the secon...

SanBio's Q2 Financials and Regenerative Medicine Push

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. announced that the Fourth Pharmaceutical Affairs Council meeting of FY2024 included a ...

SanBio Reports on Regenerative Medicine Progress

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. has been granted a new patent in the US for its cell therapy product SB623, aimed at t...

SanBio Secures US Patent for Stroke Therapy

SanBio Co (JP:4592) has released an update. SanBio Co., Ltd. experienced a minor setback in the first production run of AKUUGO, a stem cell therapy...

Comments

SanBio

News

Latest news for SanBio (OTC:SNBIF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga